158 related articles for article (PubMed ID: 34497363)
21. Usefulness of Cyclin D1/Podoplanin Dual Immunohistochemical Stain to Differentiate Malignant Mesothelioma From Reactive Mesothelial Proliferations.
Pillappa R; Wiles A; Sayeed S; Robila V
Am J Clin Pathol; 2022 Aug; 158(2):187-198. PubMed ID: 35285890
[TBL] [Abstract][Full Text] [Related]
22. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.
Sheffield BS; Hwang HC; Lee AF; Thompson K; Rodriguez S; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2015 Jul; 39(7):977-82. PubMed ID: 25634745
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations.
Tigrani DY; Weydert JA
Am J Clin Pathol; 2007 Apr; 127(4):580-4. PubMed ID: 17369133
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
25. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
26. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
Churg A; Sheffield BS; Galateau-Salle F
Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
[TBL] [Abstract][Full Text] [Related]
27. Uroplakin-IIIb as a novel immunohistochemical marker for mesothelioma.
van Pel DM; Cheung S; Ionescu DN; Churg A
Hum Pathol; 2023 Nov; 141():64-68. PubMed ID: 37776956
[TBL] [Abstract][Full Text] [Related]
28. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin.
Padgett DM; Cathro HP; Wick MR; Mills SE
Am J Surg Pathol; 2008 Jan; 32(1):123-7. PubMed ID: 18162779
[TBL] [Abstract][Full Text] [Related]
29. Mesothelioma: morphologic and immunohistochemical findings.
Churg A
Pathologie (Heidelb); 2024 Apr; ():. PubMed ID: 38568257
[TBL] [Abstract][Full Text] [Related]
30. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations.
Chang S; Oh MH; Ji SY; Han J; Kim TJ; Eom M; Kwon KY; Ha SY; Choi YD; Lee CH; Lee Y; Jung SH
Pathol Int; 2014 Dec; 64(12):607-12. PubMed ID: 25376377
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma.
Lynggård LA; Panou V; Szejniuk W; Røe OD; Meristoudis C
J Am Soc Cytopathol; 2022; 11(6):385-393. PubMed ID: 35945149
[TBL] [Abstract][Full Text] [Related]
33. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
Lagana SM; Taub RN; Borczuk AC
Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
[TBL] [Abstract][Full Text] [Related]
34. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma.
Yoshikawa Y; Sato A; Tsujimura T; Emi M; Morinaga T; Fukuoka K; Yamada S; Murakami A; Kondo N; Matsumoto S; Okumura Y; Tanaka F; Hasegawa S; Nakano T; Hashimoto-Tamaoki T
Cancer Sci; 2012 May; 103(5):868-74. PubMed ID: 22321046
[TBL] [Abstract][Full Text] [Related]
35. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms.
Cagle PT; Truong LD; Roggli VL; Greenberg SD
Am J Clin Pathol; 1989 Nov; 92(5):566-71. PubMed ID: 2479255
[TBL] [Abstract][Full Text] [Related]
37. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
38. Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma.
Terra S; Roden AC; Yi ES; Aubry MC; Boland JM
Am J Clin Pathol; 2022 Jan; 157(1):33-39. PubMed ID: 34463336
[TBL] [Abstract][Full Text] [Related]
39. Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas.
Mayall FG; Jacobson G; Wilkins R
J Clin Pathol; 1999 Apr; 52(4):291-3. PubMed ID: 10474522
[TBL] [Abstract][Full Text] [Related]
40. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
